OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhDByXenofon Baraliakos, MD, PhDJune 8th 2026
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA StudyByXenofon Baraliakos, MD, PhDJune 6th 2026
ROC-SpA: IL-17i Not Superior to Cycling TNFi Post-Failure in AxSpAByVictoria JohnsonOctober 28th 2025
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring ToolByChelsie DermanNovember 25th 2024